Karoline Kollmann

Prototype Research Fund "PRIZE 2016"

The project "Cyclotides in Cancer Therapy" from Christian Gruber, Karoline Kollmann and Dagmar Stoiber-Sakaguchi was granted the research fund "PRIZE 2016" by AWS [Link 1], supported by the Austrian Ministry of Science and Research in the amount of 145.526,98€.

PRIZE rewards new patented or patentable innovations from fundamental research at universities or in cooperation with defined research facilities. A jury selects the most promising projects in the scope of a competition to receive a research fund for creating a prototype. Prerequisite is a demand at small or medium sized companies.



Veronika Sexl, Iris Uras
 [Link 2]

SFB F47 "Myeloproliferative Neoplasms" prolongued

The funding of SFB F47 Project #06: "Targeting CDK6-regulated growth and transcription in MPN" of Veronika Sexl and Iris Uras has been prolongued for additional 4 years.

Project #06 is an important part of the SFB MPN [Link 3] research program.

 [Link 4]

SFB F28 "Jak-Stat - Signalling from Basis to Disease" prolongued

In addition, Veronika Sexl's research group of the SFB F28 "Jak-Stat - Signalling from Basis to Disease" of Mathias Müller namely "Jak-Stat involvement in leukemogenesis and NK-mediated tumor surveillance" has been granted an additional funding period.

Jak-Stat [Link 5]

All news [Link 6]


Welcome to the Institute of Pharmacology and Toxicology



Veronika Sexl
 [Link 7]

Our mission is to discover molecular mechanisms underlying physiological and pathophysiological processes in the organism. This approach is the base for rational drug design, it serves target identification and target validation in modern pharmacological research. Thereby our research offers hope for defeating some of humanity's most devastating diseases-- cancer. The mission of the institute is to perform research and education in molecular, cellular, and clinical pharmacology.

Modern medicine relies on the correct, precise use of drugs. The development of novel therapeutics over the last decades enabled us to cure a wide range of diseases. Yet many aspects still prove difficult and are awaited to be solved! The greatest challenge of our time is to translate the knowledge gathered in this post-genomic era into practice for patient-tailored treatment options - a concept termed as Personalised or Precision Medicine. Pharmacology is not only committed to find out the mechanism of action of drugs but also assists in preparing and understanding how modern drugs can be optimally exploited for the benefit of each patient in the future.

Curriculum Vitae of Veronika Sexl [Link 8]

Research [Link 9]

Publications [Link 10]


Recent publications


Leo Edlinger, Angelika Berger-Bečvař, et al.
Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1 [Link 11]
Journal: British Journal of Haematology


Iris Z. Uras, Ruth M. Scheicher, Veronika Sexl, et al.
Cdk6 contributes to cytoskeletal stability in erythroid cells [Link 12]
Journal: Haematologica


Dagmar Gotthardt, Veronika Sexl
STATs in NK-Cells: The Good, the Bad, and the Ugly [Link 13]
Journal: Frontiers in Immunology



Office: Mon. - Fri. 08:00-14:00

Student affairs: Mon. and Wed. 09:00-11:00

Tel: +43 1 25077 2901
Fax: +43 1 25077 2990
Email: Secretariat [Link 14]

Postal address:

Institute of Pharmacology and Toxicology
Veterinary University of Vienna
A-1210 Vienna, Veterinärplatz 1

Building HA, 3rd floor

Link to directions [Link 15]


Appointment with Veronika Sexl only after prior agreement per email: veronika.sexl(at)vetmeduni.ac.at [Link 16]